Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights -

Investors who purchased shares of Alto Neuroscience, Inc. during a specific timeframe have been issued a notice to potentially recover losses due to alleged false and misleading statements made by the company. The Gross Law Firm is leading the class action lawsuit against Alto Neuroscience, Inc. (NYSE: ANRO), claiming that the company's product pipeline, ALTO-100, was less effective in treating major depressive disorder than investors were led to believe.

Key Takeaways:

  • The class action lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Alto common stock or securities between February 2, 2024, and October 22, 2024.
  • The complaint alleges that Alto Neuroscience, Inc. issued false and misleading statements about the effectiveness of ALTO-100 in treating major depressive disorder, overstating the product's clinical, regulatory, and commercial prospects.
  • The alleged false statements led to artificial inflation of the company's stock, resulting in losses for investors.
  • The deadline to seek to be a lead plaintiff in the class action lawsuit is September 19, 2025.
  • Shareholders who incurred losses during the specified timeframe are encouraged to contact The Gross Law Firm regarding possible lead plaintiff appointment.
  • Appointment as lead plaintiff is not required to participate in the recovery process.

Statistics:

  • The class period for the lawsuit spans from February 2, 2024, to October 22, 2024.
  • The deadline to seek to be a lead plaintiff is September 19, 2025.
  • Shareholders who incur losses during this timeframe may be eligible for recovery.
  • The Gross Law Firm has a mission to protect the rights of investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The firm has experience seeking recovery on behalf of investors who incurred losses due to false and/or misleading statements.